[1] OLSON M W, RUZIN A, FEYFANT E, et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline[J]. Antimicrob Agents Chemother, 2006, 50(6):2156-2166.
[2] BHATTACHARYA M, PARAKH A, NARANG M. Tigecycline[J]. J Postgrad Med, 2009, 55(1):65-68.
[3] MURALIDHARAN G, MICALIZZI M, SPETH J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects[J]. Antimicrob Agents Chemother, 2005, 49(1):220-229.
[4] KALIL A C, METERSKY M L, KLOMPAS M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016, 63(5):e61-e111.
[5] MONTRAVERS P, DUPONT H, BEDOS J P, et al. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting[J]. Intensive Care Med, 2014, 40(7):988-997.
[6] 邵华, 宋一帆, 何杰, 等. 高剂量替加环素在感染性休克病人体内的药物监测及药代动力学[J]. 中国药科大学学报, 2017, 48(6):721-726.
[7] TASINA E, HAIDICH A,KOKKALI S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis[J]. Lancet Infect Dis, 2011, 11(11):834-844.
[8] 宋雨, 杨伟, 马淑, 等. 替加环素对高龄广泛耐药革兰阴性杆菌医院获得性肺炎疗效及安全性分析[J]. 中国病案, 2019, 20(4):87-91.
[9] CUNHA B A, MCDERMOTT B, NAUSHEEN S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection[J]. J Chemother, 2007, 19(6):753-754.
[10] BARON J, CAI S, KLEIN N, et al. Once daily high dose tigecycline is optimal: tigecycline PK/PD parameters predict clinical effectiveness[J]. J Clin Med, 2018, 7(3):701-707.
[11] DE PASCALE G, MONTINI L, PENNISI M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria[J]. Crit Care, 2014, 18(3):R90.
[12] XIA G, JIANG R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis[J]. Medicine: Baltimore, 2020, 99(10):e19466.
[13] XU L, WANG Y L, DU S, et al. Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia[J]. Chemotherapy, 2016, 61(6):323-330.
[14] GONG J, SU D, SHANG J, et al. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: a meta-analysis[J]. Medicine: Baltimore, 2019, 98(38):e17091.
[15] ZHA L, PAN L, GUO J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis[J]. Adv Ther, 2020, 37(3):1049-1064.
[16] CHEN Z H, SHI X Y. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens[J]. Medicine: Baltimore, 2018, 97(38):e12467.
[17] QIN Y F, ZHANG J, WU L, et al. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii[J]. Int J Clin Pharmacol Ther, 2018, 56(3):120-129.
[18] 邹靖锋, 刘媛, 邹梦林, 等. 替加环素联合头孢哌酮/舒巴坦治疗多重耐药/泛耐药鲍曼不动杆菌肺炎疗效的Meta分析[J]. 药物流行病学杂志, 2018, 27(9):588-593.
[19] 田爱庆. 替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌老年重症肺炎的临床疗效分析[J]. 吉林医学, 2019, 40(7):1495-1496.
[20] 李芳菲. 337例老年病人呼吸道细菌及耐药性分析[D]. 沈阳:中国医科大学, 2018.
[21] 胡付品, 郭燕, 朱德妹, 等. 2017年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志, 2018, 18(3):241-251.
[22] KIM W Y, MOON J Y, HUH J W, et al. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant acinetobacter baumannii pneumonia in critically ill patients[J]. PLoS One, 2016, 11(3):e0150642.
[23] NI W, LI G, ZHAO J, et al. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae[J]. Infect Dis: Lond, 2018, 50(7):507-513.
[24] GUAN X, HE L,HU B, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement[J]. Clin Microbiol Infect, 2016, 22(Suppl 1): S15-S25.
[25] ASLAN H,YAPAR N. Comparison of tigecycline and vancomycin activities in an in vitro biofilm model generated with methicillin-resistant Staphylococcus aureus[J]. Mikrobiyol Bul, 2015, 49(4):475-483.
[26] DI BELLA S, NISII C, PETROSILLO N. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature[J]. Int J Antimicrob Agents, 2015, 46(1):8-12.
[27] 孙薇, 文仲光. 替加环素致重症药疹1例[J]. 临床肺科杂志, 2015, 20(1):187-188.
[28] BERNAS ALBENIZ A, AVEIGA VALENCIA D A, ETXEBERRIA ZABALA L, et al. Acute pancreatitis in ICU secondary to treatment with tigecycline[J]. Rev Esp Anestesiol Reanim, 2017, 64(1):46-49.
[29] 徐虹, 梁月琴, 夏洪颖, 等. 6例替加环素相关性低血糖不良反应文献分析[J]. 药物流行病学杂志, 2018, 27(5):342-345.
[30] CHEN Y, LI L, ZHANG N, et al. Tigecycline-induced sustained severe hypoglycemia: a case report[J]. BMC Pharmacol Toxicol, 2019, 20(1):50.
[31] 吴冰, 陈世耀. 替加环素致肌酐水平升高1例[J]. 中国药物应用与监测, 2014, 11(4):253-254.
[32] YOON E, OH Y, JEONG S H. Klebsiella pneumoniae development of tigecycline resistance in carbapenemase-producing sequence type 147 via AcrAB overproduction mediated by replacement of the promoter[J]. Ann Lab Med, 2020, 40(1):15-20.
[33] HE F, SHI Q, FU Y, et al. Tigecycline resistance caused by rpsJ evolution in a 59-year-old male patient infected with KPC-producing Klebsiella pneumoniae during tigecycline treatment[J]. Infect Genet Evol, 2018, 66:188-191. |
